Exosomes at scale as next-generation cell free medicines: fact and fiction

---

In 2020, exosomes (also known as extracellular vesicles [EVs]) are emerging from academic laboratories and into biotechnology company led clinical trials. But this progress has, until now, been held back by the absence of a robust, scalable and proprietary purification technology. Despite this, a handful of biotechnology companies are promoting their manufacturing capabilities and progress into clinical trials. This article considers the fundamental question behind claims of scalability of EV manufacturing and its implications for the development of this promising therapeutic modality.

Please enter your email to access content Read now